Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05923905
PHASE4
Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
Sponsor: Peking University Third Hospital
View on ClinicalTrials.gov
Summary
This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients.
Official title: Randomized Double-blind Controlled Exploratory Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2023-01-18
Completion Date
2027-09-30
Last Updated
2023-11-22
Healthy Volunteers
No
Interventions
DRUG
FB1006
30mg/day
DRUG
Placebo
30mg/day
Locations (1)
Peking University Third Hospital
Beijing, Beijing Municipality, China